18
Participants
Start Date
May 17, 2018
Primary Completion Date
August 28, 2018
Study Completion Date
September 19, 2018
Glasdegib single 100 mg dose in normal healthy subjects
A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow -up.
Glasdegib single 100 mg dose in moderate renal impairment subjects
A single dose of 100 mg glasdegib tablet will be administered to subjects with moderate renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
Glasdegib single 100 mg dose in severe renal impairment subjects
A single dose of 100 mg glasdegib tablet will be administered to subjects with severe renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
University of Miami Division of Clinical Pharmacology, Miami
University of Miami, Sylvester Comprehensive Cancer Center, Miami
Prism Clinical Research LLC, Saint Paul
Lead Sponsor
Pfizer
INDUSTRY